FDA delays Opdivo decision; Axovant ups PhIII Alzheimer's costs to $135M;

@FierceBiotech: FierceBiotech Radio on Amarin's First Amendment crusade, Martin Shkreli's Twitter, and Kim Kardashian's Instagram. Listen/Subscribe | Follow @FierceBiotech

@JohnCFierce: Struggling GlobeImmune brings in financial advisers as options dwindle. Report | Follow @JohnCFierce

> Bristol-Myers Squibb ($BMY) says that the FDA is postponing its deadline for a marketing decision on Opdivo as a frontline treatment for melanoma. The new PDUFA date is November 27, giving regulators more time to review additional data filed to support the application. Release

> Axovant ($AXON) has upped the ante on its Phase III study of a new Alzheimer's drug obtained from GlaxoSmithKline ($GSK). The new estimate on the Phase III now reaches as high as $135 million, though the biotech still has plenty of cash available from its recent IPO. Axovant's share price has been falling steadily since its debut. Release

Medical Device News

@FierceMedDev: Invitae gears up for next chapter with genome management aspirations. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Google joins forces with Dexcom for miniaturized glucose monitor. Article | Follow @VarunSaxena2

@EmilyWFierce: Journalist fights Amgen subpoena in Aranesp class action suit. More from FiercePharma | Follow @EmilyWFierce

> Bad news in California: Boston Sci to close to two facilities, Abbott cuts 160+ employees. Story

> Senseonics nabs $20M in venture funding for its implantable blood glucose monitor. Article

Pharma News

@FiercePharma: OSU researchers point to vaccine-free flu protection. FierceVaccines story | Follow @FiercePharma

@EricPFierce: This is the last time Novartis will be in the top 5 of this list. FierceVaccines feature | Follow @EricPFierce

@CarlyHFierce: Fun things brewing ... for me. $HZNP PLC sends letter to $DEPO Inc board of directors. Release | Follow @CarlyHFierce

> Proxy advisers back Mylan's Perrigo quest as investor vote looms. Report

> Merck tallies 36,000 job cuts in 5 years of restructuring. Article

Vaccines News

> CMC Biologics to manufacture antibodies for Malaria Vaccines Initiative. More

> Chorus grows for reform in vaccine development process. Report

> CSL reports record $1.4B profit following Novartis flu vaccine purchase. Item

> Novavax reports positive top-line data from PhII trial of RSV vaccine. Story

> MedImmune offers up $727M to get its hands on Inovio HPV cancer vaccine. Article

CRO News

> Accelovance adding 70 jobs in Wales after a big EU buy. More

> INC's backers line up for a big Wall Street payday. Item

> WuXi advances edible bar codes, a novel approach to counter-counterfeiting. Report

> Another Indian CRO draws the ire of Western regulators. Article

> Chiltern buys Theorem to compete with CRO heavyweights. Story

Pharma Manufacturing News

> Australian pharma group says high manufacturing costs killing drug exports. Item

> Claris returns generic Lasix to market after clearing supply hurdle. More

> Chinese plant banned by EU, getting compliance help from NJ company. Report

> Sun sales, earnings pummeled by plant problems, integration costs. Story

> GSK site affected by Legionella bacteria expected to reopen in a few days. Article

Pharma Asia News

> India's Sun sees sharp Q1 profit drop, but Shanghvi not worried. More

> Pharma M&A, investment in Russia leading to exports, RBC Daily says. Article

> India's IP policies suit South Africa just fine, official says, wants New Delhi to hold the line. Story

> Opposition grows in Malaysia and New Zealand on TPP drug provisions. Report

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.